Please login to the form below

Not currently logged in

Ocrevus helps Roche stave off biosimilar threat

Roche Basel Switzerland

Its low price strategy for the CD20-targeting antibody is paying off

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

Brexit UK EU life sciences pharma biotechA rapid round up of pharma, biotech and healthcare news

Shire warms to Takeda’s latest offer, extending deadline

Takeda pharma buildingThe new offer is £5 per share higher than Takeda’s opening bid

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

Shire BasingstokeA rapid run-down of news in pharma, biotech and healthcare

Will Shire agree to extend Takeda takeover talks?

ShireUK rules mean Shire must agree to extend deadline

Sanofi appoints ex-Roche Reed as new R&D head

John Reed. RocheJohn Reed to take up post after leaving Roche last month

Tech-giants allegedly interested in Nokia’s digital health unit

Nokia digital healthBoth Samsung and Google’s Nest could be gearing up for a takeover bid

Data integrity scuppers Fresenius deal with Akorn

FreseniusHowever Fresenius could be liable to pay $129m in termination fees

Shire rebuffs Takeda bids, as Allergan bows out

ShireAllergan doesn’t intend to make a formal offer following a dip in its share prices

Business in the USAHealth coverage across state lines

Despite a total lack of legislative wins, the new administration has made its presence felt at home and abroad

  • Ho_Ung_KimStanding out in a crowd

    Celltrion Healthcare’s Ho-Ung Kim on pricing, market access and regulatory challenges for successfully developing biosimilars

  • HeadsThe diseased organisation

    Like humans, organisations can be afflicted by genetic disorders that hinder performance and threaten survival but these can be understood and cured

Featured jobs

Subscribe to our email news alerts


Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...